New rules for automakers in the successor to the North American Free Trade Agreement would require automakers to eventually produce 75 percent — up from 62.5 percent — of a vehicle’s content in North America to qualify for zero tariffs.
But the deal still awaits congressional ratification. And the changes would do little to encourage investment in the United States since “most vehicles are going to be able to get over those new thresholds pretty easily,” said Kristin Dziczek, vice president for industry, labor and economics at the Center for Automotive Research in Ann Arbor, Mich.
Even if the administration raised tariffs on foreign car imports, spurring investment in the United States, automakers would still be mindful of the volatility of Mr. Trump’s trade policies and “investment would sit on the sidelines,” Ms. Dziczek said.
Employment in the auto industry has increased slightly under Mr. Trump’s watch, to about one million in November 2018 from 955,800 in January 2017. The number of vehicles manufactured in the United States has continued to decline, even after a slight uptick last summer. According to the Reshoring Initiative, announcements to increase investment or move companies back to the United States peaked in 2016.
“We will work to fix bad trade deals and negotiate new ones. And we will protect American workers and American intellectual property, through strong enforcement of our trade rules.”
While the changes to the South Korea agreement were modest, the revised Nafta strengthens intellectual property rights in Canada. An investigation into China’s trade practices concluded that Beijing had, among other unfair trade practices, violated American intellectual property rights. As a result, the Trump administration imposed tariffs on $250 billion worth of Chinese products. The two sides are in talks over a trade deal to resolve the dispute.
“People who are terminally ill should not have to go from country to country to seek a cure — I want to give them a chance right here at home. It is time for the Congress to give these wonderful Americans the ‘right to try.’”
Mr. Trump signed “Right to Try” legislation into law in May, allowing terminally ill patients to seek access to experimental medicine that is not approved by the Food and Drug Administration.
A similar program known as compassionate use, or expanded access, has been in place since the 1970s, and the F.D.A. says it authorizes 99 percent of the requests it receives. The new law allows patients, with the approval of their doctor, to ask drug companies directly for access, rather than wait for approval by the agency.